Searched for
INDIVIOR
Job Market Turmoil: European companies cut to the chase with layoffsRising inflation and the war in Ukraine have led European companies to freeze hiring or cut jobs. Key organizations such as TSB, PKP Cargo,...- European shares steady, but geopolitical tensions weighThe pan-European STOXX 600 edged up 0.1% by 0703 GMT, after falling over 3% in the previous week.
- European shares flat; London leads on oil boostEuropean shares struggled to maintain momentum on Monday after posting gains last week, as markets faced consolidation. The pan-European ST...
- Dr Reddy's settles patent litigation with Indivior, Aquestive TherapeuticsThe stipulation of dismissal was filed pursuant to a settlement agreement that the company entered into with Indivior and Aquestive, it add...
- European shares end lower but gain for a fifth straight monthThe pan-European STOXX 600 closed 0.8% lower at 452.84 points but rose 1.4% in June, its fifth straight month of gains.
- European shares fall on inflation, pandemic woesThe pan-European STOXX 600 was down 0.2 per cent, with banks, energy and mining shares falling between 0.6 per cent and 1.0 per cent.
- London stocks gain as AstraZeneca, Indivior jump; weaker pound supportsThe blue-chip FTSE 100 index climbed 0.5%, with healthcare stocks leading the gains, while the domestically focussed mid-cap index added 0....
- European stocks rise before Brexit summit, ECB meetingThe European retail sector was among top advancers, rising after four sessions of losses.
- Dr Reddy's re-launches generic version of Suboxone in US marketIndivior is in a legal battle against the launch of the copycat version of its opioid addiction treatment by competitors.
- Market cheers new RBI boss, Sensex shoots up 629 pointsCLSA in a note said Prime Minister Narendra Modi is still a favourite to win the 2019 general election.
- DRL stock slips 5% after US court orderThe scrip was 5.30 per cent down at Rs 2,565.60 at around 02.12 pm.
- Buy Dr. Reddy's Laboratories, target Rs 3,350: Edelweiss Financial ServicesBuy Dr. Reddy's Laboratories Ltd. at a price target of Rs 3350.0 .
- Share market update: Pharma shares bullish; Dr. Reddy's Lab surges nearly 7%Benchmark NSE Nifty50 index was down 90.45 points at 10,565.75 while BSE Sensex was down 354.82 points at 35,119.69 around 11:30 am.
- Italian stocks, banks bruised by report Italy budget meeting may be delayedWeak results and broker notes caused some sharp moves lower.
- DRL takes a hit of 10% on US court orderIndivior sees a $25 million dent on its revenues due to the product of Dr Reddy's.
- Stock market update: Nifty Pharma top sectoral loser; Dr. Reddy's Labs cracks 8%The Nifty Pharma was trading 2.42 per cent down at 8,943 around 11:05 am.
- US court prevents Dr Reddy's Laboratories from selling opioid dependence treatment drugThe court has also ordered the parties to submit a final proposed injunction order on Monday.
- Dr Reddy's gets temporary restraining order on sale of generic Suboxone film in USDr Reddy's said in a BSE filing that the company remains confident in its legal positions on this patent.
- ETMarkets After Hours: Dr Reddy's gets a healthy boost; Sun TV jumps 10%The Nifty50 index of NSE closed at 9,974 with 40 constituents closing in the green and rest in the red.
- Sensex gains 162 points on firm global cues, auto data; Dr Reddy’s surges 9%Market stayed in the green on better auto sales and manufacturing data for the month of August.
Load More
